Relapsed Or Refractory Multiple Myeloma Rrmm clinical trials

Explore recruiting relapsed or refractory multiple myeloma rrmm clinical trials.

Recruiting relapsed or refractory multiple myeloma rrmm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Multiple Myeloma Rrmm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

Italy, Austria, Germany, Hungary, Spain, Norway +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma

Spain, Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib And Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM): Successor-1

Ireland, Portugal, Greece, France, Czechia, Romania +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol Phase 1/2 trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) - control arm

France, Portugal, Norway, Italy, Germany, Greece

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 1/2 trial evaluating isatuximab in combination with SAR445761 (belumosudil) and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

Norway, France, Italy, Germany, Portugal, Greece

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Or Refractory Multiple Myeloma Rrmm trials by city

Relapsed Or Refractory Multiple Myeloma Rrmm in Toronto Relapsed Or Refractory Multiple Myeloma Rrmm in Vancouver Relapsed Or Refractory Multiple Myeloma Rrmm in Montreal Relapsed Or Refractory Multiple Myeloma Rrmm in Calgary Relapsed Or Refractory Multiple Myeloma Rrmm in Edmonton Relapsed Or Refractory Multiple Myeloma Rrmm in Ottawa Relapsed Or Refractory Multiple Myeloma Rrmm in Winnipeg Relapsed Or Refractory Multiple Myeloma Rrmm in Quebec City Relapsed Or Refractory Multiple Myeloma Rrmm in Hamilton Relapsed Or Refractory Multiple Myeloma Rrmm in Kitchener Relapsed Or Refractory Multiple Myeloma Rrmm in London Relapsed Or Refractory Multiple Myeloma Rrmm in Halifax Relapsed Or Refractory Multiple Myeloma Rrmm in New York Relapsed Or Refractory Multiple Myeloma Rrmm in Los Angeles Relapsed Or Refractory Multiple Myeloma Rrmm in Chicago Relapsed Or Refractory Multiple Myeloma Rrmm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease